ArticleiScience2026
PhenoAge acceleration, serum tryptophan, and frailty in socially engaged actively aging elderly men.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biological aging varies substantially among older adults and may shape vulnerability to frailty beyond chronological age. We conducted a cross-sectional study of 928 socially engaged elderly men to examine the associations among phenotypic age (PhenoAge) acceleration, frailty-related traits, and circulating metabolites. PhenoAge acceleration, calculated from routine clinical biomarkers, was consistently associated with greater frailty severity, particularly among the old-old and those with lower physical activity. Targeted metabolomic profiling identified serum tryptophan as inversely associated with both PhenoAge acceleration and frailty-related phenotypes. Mediation analyses suggested that tryptophan statistically accounted for part of the association between biological aging and frailty. These patterns were further supported by age-matched sensitivity analyses and an independent external cohort. Together, our findings highlight the close linkage between biological aging, metabolic profiles, and frailty-related traits in actively aging populations and support the potential utility of integrating routine aging metrics with metabolic indicators to inform future longitudinal studies of healthy aging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.